Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Norihiro YamaguchiRonald H Blum

Abstract

Anthracyclines play a broad and important role in the care of patients with either operable or metastatic breast cancer. However cardiotoxicity narrows the therapeutic index of this drug class leading to potentially clinically meaningful treatment delays or discontinuations. We conducted a Bayesian network meta-analysis, a validated statistical methodology, allowing direct and indirect comparison of cardiotoxicity of different anthracycline and non-anthracycline regimens. We conducted a systematic review of prospective randomised controlled trials through MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Google Scholar comparing non-anthracycline based regimens (NON), doxorubicin (DOX), epirubicin (EPI) and liposomal doxorubicin (LD). We included studies published up to 1st January 2014 in both adjuvant and metastatic contexts. Notably, HER2/neu-targeted regimens were excluded. We assessed the studies' eligibility criteria and data collection with consensus of two independent authors. Our primary outcome measure was cardiac events grade 3 or greater (CE3) in accordance with Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. A Bayesian pairwise and network meta-analysis was conducted to estimat...Continue Reading

References

Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Feb 1, 1989·American Journal of Clinical Oncology·G N HortobagyiR S Benjamin
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeWilliam C Wood
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ChanL W Lee
Sep 28, 2004·Statistics in Medicine·G Lu, A E Ades
Apr 12, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O FeherG von Minckwitz
Oct 15, 2005·BMJ : British Medical Journal·Deborah M CaldwellJ P T Higgins
Jan 28, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Milena SantUNKNOWN EUROCARE Working Group
Feb 23, 2010·International Journal of Surgery·David MoherUNKNOWN PRISMA Group
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenJoseph C Cappelleri
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David C HoaglinAnnabel Barrett
Oct 30, 2012·Nature Medicine·Sui ZhangEdward T H Yeh
May 16, 2013·BMJ : British Medical Journal·Edward J MillsJohn P A Ioannidis
May 28, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kashif Kalam, Thomas H Marwick
Oct 8, 2013·PloS One·Anna ChaimaniGeorgia Salanti

❮ Previous
Next ❯

Citations

Jun 18, 2016·Oxidative Medicine and Cellular Longevity·Shreesh OjhaMohanraj Rajesh
Jul 7, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Mengmeng HeXingdong Zhang
Jul 21, 2020·Molecular Biology Reports·Arash Ghorbani-Abdi-SaedabadReyhane Hoshyar
Oct 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Khojasteh GhasemiMarjan Mansourian
Oct 31, 2020·Journal of Cardiovascular Pharmacology and Therapeutics·Elles M ScreeverJavid J Moslehi
Dec 31, 2019·Nanomedicine : Nanotechnology, Biology, and Medicine·Qingguo ZhaoFei Liu
Dec 15, 2020·Journal of Oncology·Vito LorussoFrancesco Giotta
Feb 20, 2021·World Journal of Surgical Oncology·Wanjing ChenYong Shen
Jan 8, 2017·Biomaterials·Leoni A Kunz-SchughartSuman Pokhrel
May 8, 2021·Current Cardiology Reports·Jayakumar SreenivasanDiwakar Jain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.